Skip to main content
Clinical Trials/JPRN-UMIN000031216
JPRN-UMIN000031216
Completed
Phase 4

A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated with Ixazomib plus Lenalidomide and Dexamethasone - A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated with Ixazomib plus Lenalidomide and Dexamethasone

Takeda Pharmaceutical Company Limited0 sites300 target enrollmentFebruary 9, 2018

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Relapsed and/or Refractory Multiple Myeloma
Sponsor
Takeda Pharmaceutical Company Limited
Enrollment
300
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 9, 2018
End Date
May 31, 2021
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Female patients who are nursing or pregnant 2\. Patients who have been treated with ixazomib 3\. Patients with hypersensitivity to any of the components of IRd therapy, their analogs or excipients 4\. Patients with another active malignancy, i.e. synchronous active malignancy or previous malignancy with a disease\-free period of less than 5 years, except for patients with carcinoma in situ (intraepithelial carcinoma) or intramucosal carcinoma judged to be cured by topical treatment 5\. Patients who are not registered with, or comply with, the guidelines of the lenalidomide management program 6\. Patients who, in the judgement of the principal investigator or investigator(s), are considered to be unsuitable for enrolment into the study

Outcomes

Primary Outcomes

Not specified

Similar Trials